A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution

Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
10/2002
10/31/2002	WO2002086134A2 Buffer solution for electroporation and a method comprising the use of the same
10/31/2002	WO2002086108A1 Method for differentiating mesenchymal stem cells into neural cells
10/31/2002	WO2002086107A2 A method for differentiating stem cells into insulin-producing cells
10/31/2002	WO2002086106A1 Method and culture medium for producing neural cells expressing tyrosine hydroxylase
10/31/2002	WO2002086104A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	WO2002086102A1 Lactic acid bacteria as agents for treating and preventing allergy
10/31/2002	WO2002086082A2 Isolation of neural stem cells using gangliosides and other surface markers
10/31/2002	WO2002086073A2 Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
10/31/2002	WO2002085965A1 Cosmetic sponges
10/31/2002	WO2002085943A2 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
10/31/2002	WO2002085416A1 Viral vectors having reduced virulence
10/31/2002	WO2002085411A1 Smallpox vaccine
10/31/2002	WO2002085390A1 Composition and method for the prevention and treatment of acne
10/31/2002	WO2002085304A2 Proliposomal drug delivery system
10/31/2002	WO2002085111A1 Flexible container system for storage of stabilized hemoglobin solutions
10/31/2002	WO2002062961A9 Peptide scaffold encapsulation of tissue cells and uses thereof
10/31/2002	WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002	WO2002058750A3 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same
10/31/2002	WO2002053185A3 Anti-inflammatory use of polycationic compounds
10/31/2002	WO2002042455A3 Modifier of organelle metalbolism
10/31/2002	WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002	WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002	WO2001093896A3 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs
10/31/2002	WO2001093895A3 A method of treatment of huntington's chorea with a protein extractable from mammalian organs
10/31/2002	WO2001093894A3 A method of treatment of parkinson's disease with a protein extractable from mammalian organs
10/31/2002	WO2001058479A9 Immunotherapy using interleukin 13 receptor subunit alpha 2
10/31/2002	WO2001047962A8 Attenuated microorganisms for the treatment of infection
10/31/2002	US20020161440 Dermal scaffold using alkaline pre-treated chitosan matrix or alkaline pre-treated chitosan and alkaline pre-treated collagen mixed matrix
10/31/2002	US20020161197 Defibrinating whole blood including red blood cells and a plasma component; filtering whole blood, whereby at least a portion of plasma is separated from red blood cells to form a red blood cell suspension, thereby purifying red blood cells
10/31/2002	US20020160971 Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor
10/31/2002	US20020160940 Modulation of endogenous gene expression in cells
10/31/2002	US20020160512 Culturing isolated hematopoietic stem cells (HSC) in culture system comprising culture medium in presence of stem cell expansion promoting factor (SCEPF) which is produced by culturing murine stromal cells
10/31/2002	US20020160510 Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
10/31/2002	US20020160509 For use in transplantation or drug screening and drug discovery in vitro
10/31/2002	US20020160471 Peptide scaffold encapsulation of tissue cells and uses thereof
10/31/2002	US20020160052 Tissue graft composition comprising liver basement membrane; graft composition can be implanted to replace or induce repair of damaged or diseased tissues
10/31/2002	US20020160051 Treating pain of bone origin and in particular related to bone diseases cause by a pathology, pre-menopause or post-menopause estrogenic deficiency, aging, cancer or trauma and to cartilaginous disorders
10/31/2002	US20020160020 Enterohemorrhagic escherichia coli vaccine
10/31/2002	US20020160016 Modified surface antigen
10/31/2002	US20020159999 Administering donor peripheral blood progenitor cells to recipient and administering a non-chronic course of an immunosuppressant, e.g., cyclosporine
10/31/2002	US20020159984 Cultivation of cells for long term engraftment
10/31/2002	US20020159983 Bioprosthetic heart valves
10/31/2002	US20020159982 Injection molding of living tissues
10/31/2002	US20020159981 A cell population cultured ex-vivo in a culture medium under conditions permitting cells of cell population to proliferate and at the same time reducing capacity of cells in utilizing copper, hence expanded yet not further differentiated
10/31/2002	US20020159977 Administering a recombinant adeno-associated virion into human suffering from hemophilia such that factor VIII nuclotide sequence are expressed at a level which provide therapeutically effective amount in the patient
10/31/2002	US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002	EP0760670A4 Cellular factors that regulate the expression of genes encoding proteins involved in cholesterol homeostasis
10/31/2002	DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002	DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002	CA2843001A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	CA2791888A1 Proliposomal drug delivery system
10/31/2002	CA2444959A1 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
10/31/2002	CA2444819A1 Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages
10/31/2002	CA2444747A1 Smallpox vaccine
10/31/2002	CA2444743A1 Viral vectors having reduced virulence
10/31/2002	CA2444706A1 Isolation of neural stem cells using gangliosides and other surface markers
10/31/2002	CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002	CA2439693A1 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
10/31/2002	CA2438833A1 Lactic acid bacteria as agents for treating and preventing allergy
10/30/2002	EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002	EP1252322A2 Herpes virus strains for gene therapy
10/30/2002	EP1252310A2 Mlp gene, nucleic acids, polypeptides and the utilization thereof
10/30/2002	EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
10/30/2002	EP1252295A1 Improved inhibition of graft versus host disease
10/30/2002	EP1252293A1 Liver tissue source
10/30/2002	EP1252182A1 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
10/30/2002	EP1251860A1 Somnogenic activity of non-pathogenic lactic acid bacteria
10/30/2002	EP1251836A2 Use of bvdu for inhibiting the growth of hyperproliferative cells
10/30/2002	EP1251747A2 Pet food composition for treating helicobacter species in pets
10/30/2002	EP1152731A4 A skin care composition that mediates cell to cell communication
10/30/2002	EP1129176A4 Embryonic stem cells
10/30/2002	EP0918509A4 Biocompatible devices with foam scaffolds
10/30/2002	CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002	CN1377414A Self-cleaving RNA sequences and their use for the control of protein synthesis
10/30/2002	CN1377274A Treatment of chronic viral infections with i (M. Vannae)
10/30/2002	CN1377257A Hybrid matrices and hybrid matrix mixtures
10/30/2002	CN1376509A Chinese medicine for treating tuberculosis
10/30/2002	CN1376508A Capsule for treating cholasma and acne and its preparing process
10/30/2002	CN1376502A Chinese medicine for treating rheumatism
10/30/2002	CN1376491A Medicine for treating myocardial infarction and angina pectoris
10/30/2002	CN1376487A Detoxicating and skin-growing ointment for treating burn
10/30/2002	CN1376486A Detoxicating and skin-growing powder for treating burn
10/30/2002	CN1376475A Medicine for threating rheumatism, rheumatoid disease, lumbar intervertebral disk protrusion, hyperosteogeny and ischias and its preparing process
10/30/2002	CN1376474A Bone-setting pill 'Jiegudan'
10/30/2002	CN1376473A Chinese medicine for treating burn and scald
10/30/2002	CN1376471A Soft capsule 'Shaganling'
10/30/2002	CN1093423C Novel brain endotheliai cell protein and methods for its use
10/30/2002	CN1093421C Process for preparing snuff to treat hepatitis B
10/30/2002	CN1093420C Process for preparing snuff to treat hepatitis A
10/30/2002	CN1093415C Chinese medicine for curing cough and asthma
10/30/2002	CN1093414C Suppository for treating prostatic disease and preparing method thereof
10/30/2002	CN1093413C Traditional Chinese medicine for treating asthma
10/30/2002	CN1093410C Process for preparing medical wine to treat rheumatic arthritis
10/30/2002	CN1093409C Fracture treating plaster
10/30/2002	CN1093404C Medicine for treating breast addiction and its preparing process
10/30/2002	CN1093403C Double regulation nutrient health-care product and its preparation method
10/30/2002	CN1093386C Starfish products
10/29/2002	US6472520 Rat PEG-3 promoter
10/29/2002	US6472374 Endometrial function
10/29/2002	US6472225 Identifying a patient donor pair based on the measured in vitro immune responses of patient lymphocytes to donor allogeneic mononuclear cells (mnc) and determining the presence of antibodies

1 ... 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 ... 1259